retatrutide clinical trial status Eli Lilly's Phase 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Retatrutide: A Triple Agonist Shaping

Youre aiming for maintenance now, not continued loss

How to read your syringe for retatrutide doses A U-100 insulin syringe has 100 graduation marks, each representing 1 unit or 0.01mL

The most common side effects reported were nausea and diarrhea: About half of adults who use GLP-1 agonists reported having experienced nausea, and about one-third of adults who use GLP-1 agonists reported having experienced diarrhea

Why 500 Calories a Day on GLP-1 Is Usually Too Low Some GLP-1 users accidentally eat 400700 calories a day because they are simply not hungry

Many symptoms improve over time as the body adjusts to treatment

Tirzepatide Products (Mounjaro, Zepbound) Tirzepatide functions through dual GLP-1 and GIP receptor activation with a half-life around five days